EUVIMEDEUVIMED entdecken
Editorial

T‐Cell Engagers in Autoimmune Diseases: What Can We Anticipate in the Near Future?

Cheng-Hsun Lu iD, Ko-Jen Li iD

International Journal of Rheumatic Diseases · 2026-11 · 29 (11)

DOI: 10.1111/1756-185x.70923 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 02.11.2026. Verfasst von Cheng-Hsun Lu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B cells are a central node in the self-sustaining immune networks of systemic autoimmune disease.Beyond differentiating into autoantibody-secreting plasmablasts and plasma cells, autoreactive B cells present antigen, provide co-stimulation, and produce cytokines that sustain reciprocal activation of T cells and innate immune cells [1].The lineage is both a pathogenic hub and a therapeutic target.That rationale has translated unevenly.Rituximab is effective in rheumatoid arthritis (RA) and several antibody-mediated diseases, yet the EXPLORER and LUNAR trials in systemic lupus erythematosus (SLE) and the RIM trial in idiopathic inflammatory myopathy (IIM) did not meet their primary endpoints [2], and randomized evidence in systemic sclerosis (SSc) is largely represented by DESIRES [3].These failures do not establish Bcell independence; they may equally reflect disease heterogeneity, variable target expression, inadequate drug exposure, or incomplete tissue depletion.REGENCY established the efficacy of the Type II anti-CD20 antibody obinutuzumab in active lupus nephritis [4], and CD19-directed chimeric antigen receptor (CAR) T-cell studies in refractory SLE, SSc, and IIM reported sustained drug-free responses after profound depletion [5].The question is no longer whether B-cell depletion works, but which compartments must be eliminated; how completely, and whether reconstitution can sustain remission while preserving protective immunity.

Autor:innen und Institutionen

  • Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Cheng-Hsun Lu, Ko-Jen Li

Zitieren

APA

Lu, C. H., & Li, K. J. (2026). T‐Cell Engagers in Autoimmune Diseases: What Can We Anticipate in the Near Future?. International Journal of Rheumatic Diseases, 29(11). https://doi.org/10.1111/1756-185x.70923

Vancouver

Lu CH, Li KJ. T‐Cell Engagers in Autoimmune Diseases: What Can We Anticipate in the Near Future?. International Journal of Rheumatic Diseases. 2026;29(11). doi:10.1111/1756-185x.70923

BibTeX
@article{Lu2026,
  author = {Lu, Cheng-Hsun and Li, Ko-Jen},
  title = {T‐Cell Engagers in Autoimmune Diseases: What Can We Anticipate in the Near Future?},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  volume = {29},
  number = {11},
  doi = {10.1111/1756-185x.70923}
}
Kostenlos starten →